FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma

FDA approved sunitinib malate (Sutent, Pfizer Inc.) for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy. More Information.  November 16, 2017

Other Hematology/Oncology (Cancer) Approvals & Safety Notifications